The mechanism of action of NEAT1 in CML is closely associated with the BCR-ABL fusion onco-protein, i.e., to the regulation of signaling pathways following the constitutive tyrosine-kinase activation [63]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.